首页 › 基金 › Frazier Life Sciences Management, L.P. › PHAT
Frazier Life Sciences Management, L.P. 对 PHAT 的持仓历史
Phathom Pharmaceuticals, Inc. · 医疗保健
Frazier Life Sciences Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 PHAT(Phathom Pharmaceuticals, Inc.)12,466,489 股,市值约 US$135.3M,约占其申报组合的 2.95%,在其申报持仓中市值排名第 9 位。 Frazier Life Sciences Management, L.P. 最近 12 个申报季度中有 12 个季度披露了 PHAT 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Frazier Life Sciences Management, L.P. 对 PHAT 的持仓演变
Frazier Life Sciences Management, L.P. 于 Q3 2023 首次披露 PHAT 持仓:10,109,279 股(约 US$104.8M)。 该持仓在 Q4 2025 达到峰值 12,466,489 股,市值约 US$206.8M。 在 12 次申报中,Frazier Life Sciences Management, L.P. 1 次增持、0 次减持、10 次保持不变。 最近一期申报(Q2 2026)显示持股 12,466,489 股、市值约 US$135.3M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 10.11M | $104.83M | 新进 |
| Q4 2023 | 10.11M | $92.30M | 持有 |
| Q1 2024 | 10.11M | $107.36M | 持有 |
| Q2 2024 | 10.11M | $104.13M | 持有 |
| Q3 2024 | 10.11M | $182.78M | 持有 |
| Q4 2024 | 10.11M | $82.09M | 持有 |
| Q1 2025 | 10.11M | $63.39M | 持有 |
| Q2 2025 | 12.47M | $119.55M | 增持 |
| Q3 2025 | 12.47M | $146.73M | 持有 |
| Q4 2025 | 12.47M | $206.82M | 持有 |
| Q1 2026 | 12.47M | $138.50M | 持有 |
| Q2 2026 | 12.47M | $135.26M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PHAT 与 13F 数据
PHAT(Phathom Pharmaceuticals, Inc.)属于医疗保健行业。我们追踪的基金中还有 30 只申报持有 PHAT,申报仓位最大的包括:Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M), NEA Management Company, LLC (US$21.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PHAT 的基金
- Medicxi Ventures Management (Jersey) Ltd 7.46M 股 · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M 股 · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M 股 · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M 股 · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M 股 · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.05M 股 · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K 股 · $6.78M · Q2 2026
更多关于 Frazier Life Sciences Management, L.P.
常见问题
How long has Frazier Life Sciences Management, L.P. held PHAT?
Frazier Life Sciences Management, L.P. has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in PHAT?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 12.47M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $135.26M, representing 2.95% of its reported portfolio and ranking #9.
Has Frazier Life Sciences Management, L.P. been buying or selling PHAT?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in PHAT. The position peaked in Q4 2025 at 12.47M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., NEA Management Company, LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.